LEGN — Legend Biotech Corporation

Legend Biotech (LEG) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q4 2025 revenue reached $306 million, a 64% increase year-over-year.
• Gross Margin: Maintained a strong gross margin of 61%, with CARVYKTI net product sales gross margin at 57%.
• Operating Margin: Improved significantly from -142% in Q2 2023 to -6% in Q4 2025.
• Adjusted Net Income: Reported positive adjusted net income of $2.5 million, a turnaround from a $59 million adjusted net loss a year ago.
• Cash Position: Ended the year with $949 million in cash and equivalents, providing financial flexibility for growth initiatives.

2. Strategic Updates and Business Highlights

• CARVYKTI Performance:
  • Net trade sales for CARVYKTI were approximately $555 million in Q4, a 66% year-over-year increase.
  • The therapy has been administered to over 10,000 patients globally and is now available in 14 markets.
  • The company achieved CARVYKTI profitability in 2025 and aims for company-wide profitability in 2026.
• Manufacturing Capacity: Expanded capacity to support annual production of 10,000 doses, with plans to increase to 20,000 doses.
• Pipeline Development: Continued focus on advancing R&D, including in vivo CAR-T programs and potential IND filings by year-end.
• Market Positioning: Emphasis on earlier-line treatment adoption, with 65% of CARVYKTI patients coming from the second to fourth line settings.

3. Forward Guidance and Outlook

• 2026 Expectations: The company anticipates CARVYKTI revenue growth of approximately 50% year-over-year, with ongoing sequential growth throughout the year.
• Profitability Goals: On track for company-wide profitability in 2026, supported by disciplined expense management and revenue growth.

4. Challenges and Points of Concern

• Competitive Pressures: The market remains competitive with emerging therapies, including bispecifics, which may impact CARVYKTI's market share in earlier lines.
• Adoption Rates: Despite growth, CAR-T therapies are still underpenetrated in earlier lines, with less than 5% of patients in the second to fourth line treated with BCMA-targeting agents.
• Regulatory Landscape: The FDA's standard review of competing therapies may affect market dynamics, and the company is preparing for potential competitive entries.

5. Notable Q&A Insights

• Growth Strategy: Management expressed confidence in achieving sequential growth in 2026, with a focus on expanding CARVYKTI's use in earlier treatment lines.
• Business Development: Interest in acquiring complementary technologies and partnerships to enhance their pipeline and market position.
• Community Adoption: Expansion into community hospitals is progressing, with educational efforts to improve physician understanding of CARVYKTI's benefits.
• Clinical Data: Anticipation of presenting clinical data for in vivo CAR-T programs in mid-2026, with ongoing studies to mitigate neurotoxic events associated with CAR-T therapies.

Overall, Legend Biotech is positioned for significant growth driven by CARVYKTI's performance and strategic initiatives, although it faces competitive pressures and challenges in market penetration.